Dr. Sylvia Escher is head of the Department of In-silico Toxicolgy at Fraunhofer ITEM. The main focus of her work is on the improvement on chemical risk assessment methodologies. She is experienced in the integration of data and data mining using toxicological databases. She analyzed in-vivo animal data to gain further insights into regulatory questions like development of read-across approaches, TTC and extrapolation factors. In the ongoing NC3R project “virtual dog” as well as the recently finished eTRANSAFE project, her group is contributing to the development of virtual control groups. Further a special focus of her work is the replacement of in-vivo animal studies by new approach methods (NAM) starting with read-across approaches (EUTOXRISK, CEFIC LRI ZET-O-MAP and EXITOX) and in ongoing projects on ab initio risk assessments (RISK-HUNT3R, ZeroPM, PARC).
Recently, Sylvia Escher also led the EFSA project on the “Development of a Roadmap for Action on New Approach Methodologies in Risk Assessment”, which analyzed data and knowledge gaps in the area of NAM based hazard and risk assessment and identified research needs. The Department of In-silico Toxicology has a lot of expertise in transcriptome analyses and PBK modelling. Sylvia Escher coordinated several (inter)national projects like EFSA NAM Roadmap, EFSA Read-Across Workflow, CEFIC LRI ZET-O-MAP. She also is engaged as work package leader (RiskHunt3r, PARC WP5.3.4) and leads several multi-disciplinary case studies on the development of IATAs (RiskHunt3r, ZeroPM, EUTOXRISK).
At SOT 2024 Dr. Sylvia Escher will also give the following lectures:
Symposium Sessions:
Integration of Metabolite Data into Read-Across Assessments
Session: New Approach Methodology and Kinetic Modeling Approaches to Support Read-Across; Talk 1111
Tuesday, March 12, 8:35 a.m. - 9:05 a.m., Grand Ballroom E‚ Salt Palace Convention Center
Modeling of Bioavailable Concentration of N-Nitrosamines Built via Endogenous Mechanisms
Session: Nitrosamines: Mechanistic Evidence to Support Subclasses with Varying Mutagenic Potency; Talk 1209
Tuesday, March 12, 4:50 p.m. - 5:10 p.m., Grand Ballroom A‚ Salt Palace Convention Center
Round table session:
Evaluation of Clinical Chemistry Parameters: Which Factors Have an Impact?
Session: Is Less More? Reduction of Animal Use through Virtual Control Groups
Wednesday, March 13, 11:25 noon - 11:35 a.m., Room 250 A‚ Salt Palace Convention Center
Dr. Sylvia Escher is also involved in the following poster discussions:
Mutamind: Benchmark Dose Modeling of N-Nitrosamines based on comet and enhanced Ames assay data
Poster 3106/P210; Session: Genotoxicity/DNA Repair
Monday, March 11, 2024, 11:45 a.m. - 1:45 p.m.
Authors: A. Londenberg, S. Chang, M. A. Djuari, K. P. Cross, G. Johnson, M. Schulz, C. Ziemann, and S. Escher
ZET-O-MAP: Identify molecular drivers of teratogenic toxicants in time-resolved NAM data
Poster 3848/P351; Session: Developmental and Juvenile Toxicology
Tuesday, March 12, 2024, 11:45 a.m. - 1:45 p.m.
Authors: M. M. Wehr, B. Schultz, H. Witters, S. Remy, K. Hollanders, M. Jacobs, and S. Escher
Evaluating the deviation of the inhalTTC group's assessment on NOAEC/LOAEC values from those of the study authors
Poster 3617/P118; Session: Risk Assessment II
Tuesday, March 12, 2024, 11:45 a.m. - 1:45 p.m.
Authors: M. Schwarz-Zocher, A. M. Api, K. Joshi, S. Collins, G. Patlewicz, A. M. Bowden, F. Boislève, M. Singal, A. Giusti, N. Sadekar, and S. E. Escher
Physiological based kinetic modelling to assess the distribution of nitrosamine formed under physiological conditions
Poster 4430/P218; Session: Mathematical Modeling
Wednesday, March 13, 2024, 2:15 p.m. - 4:15 p.m.
Authors: M. Spänig, M. Vogel, T. Hansen, U. Deppenmeier, and S. Escher